A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
Public ClinicalTrials.gov record NCT03926169. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult participants diagnosed for at least one year before the Baseline visit.
Study identification
- NCT ID
- NCT03926169
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 243 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 3, 2019 (Actual)
- Primary completion
- Feb 2, 2021 (Actual)
- Completion
- Aug 2, 2021 (Actual)
- Last update posted
- Aug 11, 2022
2019 – 2021
United States locations
- U.S. sites
- 22
- U.S. states
- 16
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Burke Pharmaceutical Research /ID# 211671 | Hot Springs | Arkansas | 71913-6404 | — |
| Bakersfield Derma & Skin Cance /ID# 211684 | Bakersfield | California | 93309 | — |
| Wallace Medical Group /ID# 215958 | Los Angeles | California | 90056 | — |
| Integrative Skin Science and Research /ID# 212550 | Sacramento | California | 95815-4500 | — |
| UC Davis Health /ID# 211436 | Sacramento | California | 95816-3300 | — |
| California Dermatology Institute /ID# 211786 | Thousand Oaks | California | 91320-2130 | — |
| CCD Research, PLLC /ID# 214479 | Cromwell | Connecticut | 06416-1745 | — |
| Advanced Medical Research /ID# 215203 | Sandy Springs | Georgia | 30328-6141 | — |
| Arlington Dermatology /ID# 219096 | Rolling Meadows | Illinois | 60008 | — |
| Tufts Medical Center /ID# 212680 | Boston | Massachusetts | 02111-1552 | — |
| Beth Israel Deaconess Medical Center /ID# 211794 | Boston | Massachusetts | 02215-5400 | — |
| Hamzavi Dermatology /ID# 212318 | Fort Gratiot | Michigan | 48059 | — |
| University of Minnesota /ID# 212319 | Minneapolis | Minnesota | 55455-0356 | — |
| Minnesota Clinical Study Center /ID# 211979 | New Brighton | Minnesota | 55112 | — |
| Skin Specialists, PC /ID# 211675 | Omaha | Nebraska | 68144 | — |
| Montefiore Medical Center - Moses Campus /ID# 211800 | The Bronx | New York | 10467 | — |
| Oregon Medical Res Center PC /ID# 211796 | Portland | Oregon | 97223 | — |
| Penn State Hershey Medical Ctr /ID# 211659 | Hershey | Pennsylvania | 17033-2360 | — |
| Rhode Island Hospital /ID# 211807 | Providence | Rhode Island | 02903 | — |
| Modern Research Associates, PL /ID# 215202 | Dallas | Texas | 75231 | — |
| Virginia Clinical Research, Inc. /ID# 215959 | Norfolk | Virginia | 23507 | — |
| Premier Clinical Research /ID# 211799 | Spokane | Washington | 99202 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03926169, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 11, 2022 · Synced Oct 29, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03926169 live on ClinicalTrials.gov.